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Abstract. – Understanding the risks of ather-
osclerotic cardiovascular disease (CVD) allows
for better patient education and management.
Multiple risk models have been validated in large
patient populations and provide insights into the
risks associated with CVD.When assessing such
risks, we suggest using a model that predicts
myocardial infarction, cardiovascular death,
and/or cerebrovascular events. In this review, we
analyze several risk models and stratify the risks
associated with CVD. We suggest that appropri-
ate profiling of patients at-risk of CVD will lead to
better physician recognition and treatment of
modifiable risk factors, appropriate application of
ATP III treatment for hyperlipidemia, and achiev-
ing optimal blood pressure control.
Key Words:
Coronary heart disease, Cardiovascular disease,
Cardiovascular multiple risk factors, C Reactive Protein,
Myocardial infarction, Borderline risk factors.
Introduction
Atherosclerotic cardiovascular disease (CVD)
afflicts the majority of adults over the age of 60
years and the prevalence of coronary heart disease
(CHD) is approximately one-half that of total
CVD1. The presence of atherosclerosis in one or-
gan system is predictive of atherosclerosis in other
vascular beds. As such, the presence of non-coro-
nary atherosclerotic disease is a CHD risk equiva-
lent2. According to the Framingham Heart Study,
the lifetime risk for CHD in individuals age 40 was
49% and 32% for men and women, respectively. In
patients free from CHD at age 70, the lifetime risk
for males and females is 35% and 24%, respective-
ly. The lifetime risk of CHD is commensurate with
the burden of risk factors (Figure 1)3. According to
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the worldwide INTERHEART study, many of
these factors are modifiable, as nine such risk fac-
tors accounted for over 90 percent of the popula-
tion attributable risk of a first MI4. These factors in-
clude smoking, alcohol, dyslipidemia, hyperten-
sion, diabetes mellitus, obesity, psychosocial fac-
tors, consumption of fruits and vegetables, and
physical activity.
In this review we discuss the predictive value
of the risk factors and the use of multivariate risk
models to estimate cardiovascular risks. We high-
light the utility of these risk models in patient
management, particularly in primary prevention
of CVD events.
Methods
Population based studies and guidelines on risk
stratification and prediction of cardiovascular dis-
ease, published from 1998 to 2012, were re-
viewed. While, little substantive information was
found, the systematic review of Willis et al5 as-
sesses the effectiveness of recruiting participants
using CVD risk scores and offers advice on modi-
fications to reduce CVD morbidity and mortality.
Who Should Undergo Risk Estimation
Patients at High Risk
Individuals with established CVD; diabetes
mellitus; chronic renal failure; and hereditary
dyslipidemias are at high risk for the develop-
ment of CVD events and do not need additional
risk stratification.
Patients at Increased Risk
The United States National Cholesterol Educa-
tion Program Expert Panel on Detection, Evalua-
2014; 18: 365-373
Figure 1. Lifetime risk of cardiovascular disease. Cumulative lifetime incidence of cardiovascular disease, adjusted for the
competing risk of death, according to the aggregate risk factor (RF) burden in men and women in the Framingham Heart Study
at age 50 who did not have clinical cardiovascular disease. The lifetime risk ranged from 5 percent in men and 8 percent in
women with all optimal risk factors to 69 percent in men and 50 percent in women with 2 major risk factors.
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Key Point: Individuals with more than one risk
factor for CHD should undergo risk stratification.
Borderline Risk Factors
The frequency and predictive value of blood
pressure, LDL and HDL cholesterol, glucose in-
tolerance, and smoking was evaluated in a study
of white individuals 35 to 74 years of age with-
out CHD in the Framingham Heart Study and the
Third National Health and Nutrition Examination
Survey (NHANES III). Six CHD events occurred
in more than 90% of individuals who had at least
one risk factor and 8% occurred in individuals
who had borderline levels of multiple risk fac-
tors. In NHANES III, approximately 60% of men
and 50% of women had one or two risk factors,
and 26% of men and 41% of women had at least
one borderline risk factor.
The available evidence in the present guide-
lines does not support the use of multiple risk
factor interventions in the low to medium risk in-
dividuals. No guidelines address the lowest risk
population, which may benefit from early recog-
nition and intervention.
tion, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III or ATP III)
guidelines recommend estimating risk in individu-
als with two or more risk factors1. However, this ap-
proach excludes many individuals who are at in-
creased lifetime risk and for whom primary preven-
tative strategies would be of value. Future revision
of such guidelines is likely to include estimation of
risk in individuals, with only one risk factor.
Predictive Value of Risk Factors
In the general population, most have one or
more risk factors for CHD and over 90% of CHD
events occur in individuals with at least one risk
factor4,6. Stamler et al7 reviewed data from the
Multiple Risk Factor Intervention Trial (MRFIT)
and the Chicago Heart Association Project in In-
dustry. When comparing the group with > 1 risk
factor to the low risk group, after an average fol-
low-up of 16 years for MRFIT and 22 years for
the Chicago trial, patients with > 1 factor had
significantly higher CHD mortality (0.2% to
8.8% versus 1.5% to 38% percent for those with
≥ 1 risk factor).
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Figure 2. Cumulative absolute risk of cardiovascular disease at five years. Cumulative absolute risk of cardiovascular disease
(CVD) at five years according to systolic blood pressure and specified levels of other risk factors. The reference category is a
no diabetic, nonsmoking 50 year old woman with a serum total cholesterol (TC) of 154 mg/dL (4.0 mmol/L) and HDL-choles-
terol of 62 mg/dL (1.6 mmol/L).
Key Point: We suggest that patients deemed low
risk for CVD events may also benefit from early
early recognition and intervention.
Multiple Risk Factors
In addition to the ATP III study, the increase in
risk when multiple risk factors exist, has also
been noted by other in both Western and Asian
populations8-10. When a combination of choles-
terol ≥ 200 mg/dL (≥ 5.2 mmol/L), hypertension,
and cigarette smoking were present, both men
and women had an increase in the relative risk of
CHD 5.5 and 5.7, respectively, cardiovascular
disease 4.1 and 4.5, respectively, and all-cause
mortality 3.2 and 2.3, respectively. The indepen-
dent effects of systolic pressure and total choles-
terol were illustrated in a larger study of 380,000
individuals from Asia, Australia, and New
Zealand10. This study demonstrated for every 10
mmHg increase in systolic pressure, there was an
associated 21% to 34% increase in risk at all lev-
els of serum cholesterol. Adjustment for other
risk factors had no effect on these findings. Pa-
tients with higher levels total cholesterol (≥ 240
mg/dL [) and systolic pressure (≥ 160 mmHg)
had a seven-fold increase in CHD and an eight-
fold increase in stroke, compared to patients with
lower levels of total cholesterol (< 183 mg/dL)
and systolic pressure (< 130 mmHg).
Key Point: The presence of multiple risk factors
portends a significantly higher risk for cardiovas-
cular disease and mortality.
Multivariate Risk Models
A number of multivariate risk models have
been developed for estimating the risk of cardio-
vascular events in apparently healthy, asympto-
matic individuals based upon assessment of mul-
tiple variables4,6-10. Many of the risk factors are
recognized as producing a graded increase in risk
(Figure 2)8. These models estimate risk of an in-
dividual over the next ten years.
Framingham Risk Scores
We are going to keep a validation study on the
first Framingham CHD found that the predictor
performed well for prediction of CHD events in
black and white women and men11,12. The Fram-
ingham risk score was modified by ATP III for
use in their recommendations for screening for
and treatment of dyslipidemia (Table I a-b)1. The
modifications included elimination of diabetes
mellitus from the algorithm, broadening of the
367
Cardiovascular risk in patients without known cardiovascular disease
368
R.G. Carbone, M.F. Algahim, S. Rizzo, A Monselise, R.A. Dart, G.H. Almassi, D.D. Gutterman
A
g
e,
ye
ar
s
P
o
in
ts
To
ta
l
ch
o
le
st
er
o
l
m
g
/d
L
(m
m
o
l/
L)
20
to
34
-
9
A
ge
20
to
39
A
ge
40
to
49
A
ge
50
to
59
A
ge
60
to
69
A
ge
70
to
79
35
to
39
-
4
<
16
0
(3.
4)
0
0
0
0
0
40
to
44
0
16
0
to
19
9
(3.
4
to
5.
15
)
4
3
2
1
0
45
to
49
3
20
0
to
23
9
(5.
17
to
6.
18
)
7
5
3
1
0
50
to
54
6
24
0
to
27
9
(6.
2
to
7.
21
)
9
6
4
2
1
55
to
59
8
≥
28
0
(7.
24
)
11
8
5
3
1
60
to
64
10
65
to
69
11
A
ge
20
to
39
A
ge
40
to
49
A
ge
50
to
59
A
ge
60
to
69
A
ge
70
to
79
70
to
74
12
N
o
n
sm
o
ke
r
0
0
0
0
0
75
to
79
13
Sm
o
ke
r
8
5
3
1
1
H
D
L
ch
o
le
st
er
o
l
Sy
st
o
lic
bl
o
o
d
m
g/
dL
(m
m
o
l/L
)
Po
in
ts
pr
es
su
re
m
m
H
g
U
n
tr
ea
te
d
Tr
ea
te
d
≥
60
(1.
55
)
-
1
<
12
0
0
0
50
to
59
(1.
29
to
1.
53
)
0
12
0
to
12
9
0
1
40
to
49
(1.
03
to
1.
27
)
1
13
0
to
13
9
1
2
<
40
(1.
03
)
2
14
0
to
15
9
1
2
≥
16
0
2
3
Po
in
tt
o
ta
l
10
-
ye
a
rs
ri
sk
,
pe
rc
en
t
Po
in
tt
o
ta
l
10
-
ye
a
r
ri
sk
,
pe
rc
en
t
0
1
9
5
1
1
10
6
2
1
11
8
3
1
12
10
4
1
13
12
5
2
14
16
6
2
15
20
7
3
16
25
8
4
≥
17
≥
30
Ta
b
le
Ia
.F
ra
m
in
gh
am
/A
TP
II
Ip
o
in
ts
co
re
s
in
m
en
.
Th
es
e
ris
k
es
tim
at
es
fo
r
th
e
de
v
el
o
pm
en
to
fc
o
ro
n
ar
y
he
ar
td
ise
as
e
do
n
o
ta
cc
o
u
n
tf
o
r
al
li
m
po
rt
an
tc
ar
di
o
v
as
cu
la
r
ris
k
fa
ct
o
rs
.
N
o
ti
n
cl
u
de
d
ar
e
di
ab
et
es
m
el
lit
u
s
(w
hi
ch
is
co
n
-
si
de
re
d
a
C
H
D
e
qu
iv
a
le
n
t),
fa
m
ily
hi
st
o
ry
o
f
C
H
D
,
a
lc
o
ho
l
in
ta
ke
,
a
n
d
th
e
se
ru
m
C
-
re
a
c
tiv
e
pr
o
te
in
c
o
n
c
e
n
tr
a
tio
n
.
A
da
pt
e
d
fr
o
m
A
du
lt
Tr
e
a
tm
e
n
t
Pa
n
e
l
II
I
a
t
ht
tp
://
w
w
w
.
n
hl
bi
.
n
ih
.
go
v
/T
he
po
in
tt
o
ta
li
s
de
te
rm
in
ed
in
ea
ch
ca
te
go
ry
an
d
th
e
10
-
ye
ar
ris
k
de
te
rm
in
ed
in
th
e
bo
tto
m
ro
w
.
369
Cardiovascular risk in patients without known cardiovascular disease
Th
es
e
ris
k
es
tim
at
es
fo
r
th
e
de
v
el
o
pm
en
to
fc
o
ro
n
ar
y
he
ar
td
ise
as
e
do
n
o
ta
cc
o
u
n
tf
o
r
al
li
m
po
rt
an
tc
ar
di
o
v
as
cu
la
r
ris
k
fa
ct
o
rs
.
N
o
ti
n
cl
u
de
d
ar
e
di
ab
et
es
m
el
lit
u
s
(w
hi
ch
is
co
n
-
si
de
re
d
a
C
H
D
e
qu
iv
a
le
n
t),
fa
m
ily
hi
st
o
ry
o
f
C
H
D
,
a
lc
o
ho
l
in
ta
ke
,
a
n
d
th
e
se
ru
m
C
-
re
a
c
tiv
e
pr
o
te
in
c
o
n
c
e
n
tr
a
tio
n
.
A
da
pt
e
d
fr
o
m
A
du
lt
Tr
e
a
tm
e
n
t
Pa
n
e
l
II
I
a
t
ht
tp
://
w
w
w
.
n
hl
bi
.
n
ih
.
go
v
/T
he
po
in
tt
o
ta
li
s
de
te
rm
in
ed
in
ea
ch
ca
te
go
ry
an
d
th
e
10
-
ye
ar
ris
k
de
te
rm
in
ed
in
th
e
bo
tto
m
ro
w
.
A
g
e,
ye
ar
s
P
o
in
ts
To
ta
l
ch
o
le
st
er
o
l
m
g
/d
L
(m
m
o
l/
L)
20
to
34
-
7
A
ge
20
to
39
A
ge
40
to
49
A
ge
50
to
59
A
ge
60
to
69
A
ge
70
to
79
35
to
39
-
3
<
16
0
(3.
4)
0
0
0
0
0
40
to
44
0
16
0
to
19
9
(3.
4
to
5.
15
)
4
3
2
1
1
45
to
49
3
20
0
to
23
9
(5.
17
to
6.
18
)
8
6
4
2
1
50
to
54
6
24
0
to
27
9
(6.
2
to
7.
21
)
11
8
5
3
2
55
to
59
8
≥
28
0
(7.
24
)
13
10
7
4
2
60
to
64
10
65
to
69
12
A
ge
20
to
39
A
ge
40
to
49
A
ge
50
to
59
A
ge
60
to
69
A
ge
70
to
79
70
to
74
14
N
o
n
sm
o
ke
r
0
0
0
0
0
75
to
79
16
Sm
o
ke
r
9
7
4
2
1
H
D
L
ch
o
le
st
er
o
l
Sy
st
o
lic
bl
o
o
d
m
g/
dL
(m
m
o
l/L
)
Po
in
ts
pr
es
su
re
m
m
H
g
U
n
tr
ea
te
d
Tr
ea
te
d
≥
60
(1.
55
)
-
1
<
12
0
0
0
50
to
59
(1.
29
to
1.
53
)
0
12
0
to
12
9
1
3
40
to
49
(1.
03
to
1.
27
)
1
13
0
to
13
9
2
4
<
40
(1.
03
)
2
14
0
to
15
9
3
5
≥
16
0
4
6
Po
in
tt
o
ta
l
10
-
ye
a
rs
ri
sk
,
pe
rc
en
t
Po
in
tt
o
ta
l
10
-
ye
a
r
ri
sk
,
pe
rc
en
t
<
9
<
1
17
5
9
1
18
6
10
1
19
8
11
1
20
11
12
1
21
14
13
2
22
17
14
2
23
22
15
3
24
27
16
4
≥
25
≥
30
Ta
b
le
Ib
.F
ra
m
in
gh
am
/A
TP
II
Ip
o
in
ts
co
re
s
in
w
o
m
en
.
370
age range, and inclusion of hypertension treat-
ment and age-specific points for smoking, and
total cholesterol.
The Framingham/ATP III criteria were used to
estimate the distribution of CHD risk in the United
States in NHANES III among 11,611 patients
without self-reported CHD, stroke, peripheral ar-
terial disease, or diabetes13. Patients were catego-
rized based on risk of CHD at 10 years – low (<
10%), intermediate (10-20%), and high risk (>
20%). 82% of the patients were found to be the
low risk, 16% were intermediate, and 3% were in
the high risk group. Predictably, high risk was as-
sociated with increased age and the male gender.
The Framingham risk scores do not include all
of the potential adverse consequences of athero-
sclerosis such as stroke, transient ischemic at-
tack, claudication, and heart failure. These out-
comes were considered in the development of the
2008 Framingham general cardiovascular risk
score, which was shown to have reliable predic-
tive ability (Table II a-b)14. The estimated risk of
developing a cardiovascular event will be higher
with this risk score than with those that predict
only CHD events.
Several studies suggest that the Framingham cri-
teria either overestimate or underestimate the risk of
initial CHD events in other ethnic populations and
in patients older than age 85 years12,15-22. It is un-
clear if these differences are real or if they are due
to differences in research methodology15,22. Multi-
ple models, including SCORE and QRISK2, have
been developed in an attempt to provide better pre-
dictive accuracy for European patients18-24.
Key Point: Framingham Risk score performs
well for risk prediction of CHD events in black
and white women and men. Its validity for other
ethnic groups is not well established.
Score
SCORE included data on more than 200,000
patients pooled from cohort studies in 12 Euro-
pean countries18-22. Variables included age, gen-
der, systolic blood pressure, total cholesterol,
HDL cholesterol, and cigarette smoking. The
mean follow-up was 13 years, with the end point
being cardiovascular death. A unique aspect of
SCORE is that separate risk scores were calculat-
ed for high- and low-risk regions of Europe. The
predictive value of SCORE was high in each
component study cohort. SCORE differs from
the earlier Framingham risk models in two ways:
it estimates the ten-year risk of any first fatal ath-
erosclerotic event and it estimates only CVD
mortality. SCORE was recommended in the 2007
European Society of Cardiology guidelines on
cardiovascular disease prevention in clinical
practice21.
Discussion
While the current risk models provide good
stratification and definition of high-risk CVD pa-
tients, they provide false reassurance for those
deemed low risk (Figure 1)3,6. Patients with less
than 10% likelihood of developing CVD are con-
sidered low risk. However, this does not consider
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Input: Results:
Age yr † Risk Factors
Sys BP mmHg † Risk % †
Total Chol mg/dL † Decimal precision 2 †
HDL Chol mg/dL †
On hypertension No (2.76157) †
medication
Cigarette smoker No (0) †
Diabetes present No (0) †
Table IIa. Formula Risk Factors = (ln(Age) *2.32888) + (ln(TotalChol) *1.20904) – (ln(HDLChol) * 0.70833) + (ln(SysBP)
*SysBPFactor) + Cig + DM – 26.1931 Risk = 100 * (1 – 0.9501 e (RiskFactors).
Framingham 10Year Risk of General Cardiovascular Disease in Women. This risk assessment tool is based on the Cox regres-
sion model of proportional hazards. Cardiovascular disease includes coronary disease, cerebrovascular disease, peripheral vas-
cular arterial disease and heart failure. It may be applied to women who have had no prior history of cardiovascular disease.
the lifetime risk, which may be high and amenable
to early intervention3,26-28. Many of the current
models were derived from cohort studies that in-
cluded persons not on medications. The more fre-
quent use of cholesterol lowering and antihyper-
tensive medications in recent years and assess-
ment of factors that might alter the risk for vascu-
lar events have become more complicated29. Some
risk models do not include cardiovascular out-
comes such as stroke, heart failure, or develop-
ment of symptomatic peripheral arterial disease.
Potential Improvements to the Risk Models
Potential ways to enhance the estimation of
cardiovascular risk include the addition of labo-
ratory tests to the models or to estimate lifetime
risk in individuals with a low ten-year risk30. Bio-
markers such as CRP, imaging tests such as coro-
nary calcium score or carotid intima-media thick-
ness, exercise testing or screening for novel
genotypes are potential improvements to current
risk models.
Lifetime Risk
The Framingham Heart Study assessed long-
term outcomes according to risk status in individ-
ual’s age 50 years without known cardiovascular
disease3. Participants were defined as having op-
timal risk factors – total cholesterol < 180 mg/dL
(4.65 mmol/L), blood pressure < 120/< 80
mmHg, no smoking, and no diabetes. The risk in-
creased progressively with the number and inten-
sity of risk factors (Figure 1). Participants with
optimal risk factors when compared to those with
≥ 2 major risk factors, had lower lifetime risks of
cardiovascular disease (5% versus 69% in men,
and 8% versus 50% in women), and longer medi-
an survivals (> 39 versus 28 years in men and >
39 versus 31 years in women). Although the dif-
ference was less pronounced, the lifetime cardio-
vascular risk was significantly lower in partici-
pants with optimal risk factors compared to those
with ≥ 1 suboptimal risk factor (5% versus 36%
in men and 8% versus 27% in women).
However, many individuals with a low ten-year
risk have a high lifetime risk. This was illustrated
in the MESA and CARDIA trials29. Ten year and
lifetime risks were assigned to each individual and
patients were then divided into three groups: low
(< 10%) and low lifetime risk (< 39%); low ten
year and high lifetime risk (≥ 39%); and high ten
year risk or diabetes. The group with a low ten year
and high lifetime risk had both a significantly
greater burden of baseline subclinical atherosclero-
sis as well as a significantly higher rate of coronary
artery calcification (CAC) progression than the
group with a low ten year and low lifetime risk.
Key point: The use of additional tests to define
the baseline atherosclerosis burden significantly
improves the predictability power of the risk
model.
Conclusions
Recommendations for Risk Assessment in a
Presumed “Low Risk” Population Estimation of
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Framingham 10Year Risk of General Cardiovascular Disease in Women. This risk assessment tool is based on the Cox regres-
sion model of proportional hazards. Cardiovascular disease includes coronary disease, cerebrovascular disease, peripheral vas-
cular arterial disease and heart failure. It may be applied to women who have had no prior history of cardiovascular disease.
Input: Results:
Age yr † Risk Factors
Syst BP mmHg † Risk % †
Total Chol mg/dL † Decimal precision 2 †
HDL Chol mg/dL †
On hypertension No (1.93393) †
medication
Cigarette smoker No (0) †
Diabetes present No (0) †
Table IIb. Formula Risk Factors = (ln(Age) *3.06117) + (ln(TotalChol) * 1.12370) – (ln(HDLChol) *0.93263) +(ln(SysBP)
*SysBPFactor) + Cig + DM - 23.9802. Risk = 100 * (1 – 0.88936 e (RiskFactors).
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cardiovascular risk using multivariate risk profil-
ing were strongly endorsed by an AHA/ACC Sci-
entific Statement in 199931. The appropriate ap-
plication of risk score assessment in patient man-
agement includes the following considerations:
(1) The ATP III recommendations for the treat-
ment of hyperlipidemia, which is modified by the
coexistence of CHD and the number of cardiac
risk factors1. (2) The goal blood pressure in pa-
tients at high risk for the development of CVD is
controversial, with some experts suggesting use
of risk models and others not31. (3) It has been
suggested that determination of a patient’s calcu-
lated cardiovascular risk profile, and presentation
of the results to the patient, may improve compli-
ance with risk reduction measures (Table I a-b).
(4) It has also been suggested that determination
of a patient’s risk profile should improve physi-
cian recognition and treatment of modifiable risk
factors.
Under-recognition of hypertension, hyperlipi-
demia and other risk factors, when presenting as
a single, modifiable risk factor remains a com-
mon problem, particularly in the “low risk” pop-
ulation. Thus, routine risk assessment may ap-
propriately identify even a presumed “low-risk”
profile, leading to more appropriate, cost-effec-
tive intervention and improved outcomes.
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